Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center
Authors
Keywords
-
Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 13, Issue 2, Pages 293-302
Publisher
Wiley
Online
2014-11-18
DOI
10.1111/jth.12790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- What Does Elevated High-Sensitive Troponin I in Stroke Patients Mean: Concomitant Acute Myocardial Infarction or a Marker for High-Risk Patients
- (2013) B. Anders et al. CEREBROVASCULAR DISEASES
- Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
- (2012) Marie Scully et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
- (2012) Y. Benhamou et al. HAEMATOLOGICA
- Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and Inflammatory Biomarkers
- (2012) Oktay Tutarel et al. PLoS One
- Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura
- (2012) Paul Coppo et al. PRESSE MEDICALE
- Autoimmune Thrombotic Microangiopathy: Advances in Pathogenesis, Diagnosis, and Management
- (2012) Han-Mou Tsai SEMINARS IN THROMBOSIS AND HEMOSTASIS
- The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura
- (2012) Josefin-Beate Holz TRANSFUSION AND APHERESIS SCIENCE
- A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
- (2011) M. Scully et al. BLOOD
- Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
- (2011) Antoine Froissart et al. CRITICAL CARE MEDICINE
- Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single-center Experience
- (2010) Kaushang Gandhi et al. CLINICAL CARDIOLOGY
- Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience
- (2010) Paul Coppo et al. PLoS One
- Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura
- (2010) Bernd Jilma et al. THROMBOSIS AND HAEMOSTASIS
- Survival and relapse in patients with thrombotic thrombocytopenic purpura
- (2009) J. A. K. Hovinga et al. BLOOD
- Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13
- (2009) C. HUGHES et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review
- (2008) Ali S. Wahla et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Cardiac Troponin and Outcome in Acute Heart Failure
- (2008) W. Frank Peacock et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started